PT-141 Peptide Research: 7 Key Findings on Melanocortin Receptors, Bremelanotide and Clinical Evidence
Understanding the cyclic heptapeptide, MC4R-associated signalling, melanocortin pharmacology, the RECONNECT clinical trials and the distinction between approved bremelanotide and laboratory research materials.
PT-141 peptide research examines bremelanotide, a synthetic cyclic heptapeptide developed from the melanocortin peptide family. Its principal scientific interest involves melanocortin receptor activation, particularly signalling associated with MC4R in the central nervous system.
Unlike many experimental research peptides, bremelanotide has progressed through large controlled clinical trials and received FDA approval as the active ingredient in Vyleesi, a prescription medicine for a narrowly defined condition.
That distinction is essential. Approval of a specific bremelanotide pharmaceutical product does not establish that independently supplied PT-141 research vials have the same quality, formulation, safety or regulatory status.
PT-141 peptide research also requires precision about its mechanism. Bremelanotide interacts with several melanocortin receptors rather than functioning as an exclusively selective MC4R agonist. Although MC4R is an important candidate in its central effects, the exact pathway responsible for the approved medicine’s clinical action is not fully established.
This article examines seven major findings, including chemical structure, receptor pharmacology, central nervous system signalling, human clinical outcomes, cardiovascular effects, adverse reactions and laboratory quality assessment. PT-141 peptide research
1. PT-141 Peptide Research: Structure and Melanocortin Origins
PT-141 is another designation for bremelanotide, a synthetic cyclic peptide related to alpha-melanocyte-stimulating hormone, abbreviated α-MSH.
Alpha-MSH is derived from the proopiomelanocortin precursor and participates in melanocortin receptor signalling.
Bremelanotide was developed through modifications of melanocortin peptide structures, including compounds related to Melanotan II.
Molecular specifications
| Property | Scientific information |
|---|---|
| Compound | Bremelanotide |
| Research designation | PT-141 |
| Peptide class | Synthetic cyclic heptapeptide |
| Structural family | Alpha-MSH-derived melanocortin analogue |
| Residue sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Amino acid residues | 7 |
| Molecular formula | C50H68N14O10 |
| Approximate molecular mass | 1025.2 Da |
| CAS number | 189691-06-3 |
| Principal pharmacological class | Melanocortin receptor agonist |
| Important receptor targets | MC1R, MC3R and MC4R |
| FDA-approved pharmaceutical | Vyleesi, for a specific indication |
The structure contains a cyclised portion involving the side chains of aspartic acid and lysine. The peptide also contains a D-phenylalanine residue and an N-terminal acetyl group.
These details distinguish bremelanotide from the natural α-MSH sequence. PT-141 peptide research
Why is cyclisation important?
Cyclisation constrains the peptide’s conformation and can influence receptor interactions.
However, cyclisation alone does not establish a particular half-life or clinical effect.
Is PT-141 identical to Melanotan II?
No. They are closely related melanocortin analogues, but their chemical structures differ.
Findings involving Melanotan II cannot automatically be attributed to bremelanotide.
Why the precise structure matters
PT-141 peptide research depends on identifying the intended molecule rather than treating all melanocortin analogues as interchangeable.
Changes in residue identity, stereochemistry or terminal structure may affect receptor binding and experimental behaviour. PT-141 peptide research
2. PT-141 Peptide Research and Melanocortin Receptor Signalling
Melanocortin receptors belong to the G protein-coupled receptor family.
Five receptor subtypes are commonly designated MC1R through MC5R.
Each has distinct tissue distributions and physiological roles.
MC1R and pigmentation
MC1R is strongly associated with pigmentation biology.
Activation of this receptor in melanocytes can influence melanin production.
This receptor interaction is relevant to the pigmentation-related adverse effects described in pharmaceutical bremelanotide labelling.
MC3R and central signalling
MC3R is expressed in several tissues, including regions of the nervous system.
It participates in complex neuroendocrine and metabolic processes.
MC4R and neuronal signalling
MC4R is widely studied for its role in central nervous system pathways involving energy balance, autonomic regulation and other physiological responses.
It is a major focus of experimental bremelanotide research.
Does bremelanotide activate only MC4R?
No.
FDA pharmacology reviews describe bremelanotide as a melanocortin receptor agonist with activity at multiple receptor subtypes, including MC1R, MC3R and MC4R.
What happens after receptor activation?
Melanocortin receptors commonly signal through Gs-associated pathways that increase intracellular cyclic AMP.
Cyclic AMP can activate protein kinase A and other downstream signalling processes.
Does receptor activation prove a behavioural outcome?
No.
Receptor activation is a molecular event. Complex behavioural responses depend on neuronal circuits and additional physiological factors.
Is the clinical mechanism fully understood?
The current prescribing information states that the mechanism by which bremelanotide improves HSDD in women is unknown.
Scientific interpretation
PT-141 peptide research provides substantial evidence of melanocortin receptor activity, but the precise relationship between individual receptor subtypes and clinical outcomes remains incompletely resolved.
3. PT-141 Peptide Research and Central Nervous System Pathways
The central nervous system is an important focus of melanocortin pharmacology.
Researchers have examined how melanocortin receptor activation influences neuronal networks associated with motivation and reproductive behaviour.
Why study the hypothalamus?
The hypothalamus participates in endocrine regulation, autonomic responses and motivated behaviour.
Several melanocortin receptors are expressed in hypothalamic regions.
The role of MC4R
MC4R signalling has been investigated in animal experiments involving reproductive and motivational responses.
These studies provide mechanistic hypotheses for compounds such as bremelanotide.
What about dopamine?
Dopaminergic signalling participates in reward, motivation and other behavioural processes.
Some experimental models suggest interactions between melanocortin pathways and dopamine-associated neuronal systems.
However, these findings do not establish bremelanotide as a direct dopamine receptor agonist.
Does PT-141 act like sildenafil?
No.
Sildenafil inhibits phosphodiesterase type 5, an enzyme involved in cyclic GMP signalling.
Bremelanotide acts through melanocortin receptor pharmacology.
The two compounds therefore have different primary molecular targets.
What about nitric oxide?
Nitric oxide contributes to several physiological signalling systems.
Although downstream interactions may occur in certain experimental contexts, PT-141 should not be described as a conventional nitric oxide donor.
Can animal findings establish human effectiveness?
Animal studies can support mechanistic hypotheses, but clinical conclusions require appropriately designed human trials.
Scientific interpretation
PT-141 peptide research links melanocortin signalling with neural pathways involved in motivated behaviour.
The evidence does not justify describing PT-141 as a universal enhancer of motivation or sexual performance.
4. PT-141 Peptide Research: RECONNECT Clinical Trial Evidence
The strongest clinical evidence for bremelanotide comes from the RECONNECT phase 3 programme.
These studies examined women with acquired, generalised hypoactive sexual desire disorder, abbreviated HSDD.
What is acquired, generalised HSDD?
The approved indication concerns low sexual desire that develops after a period without the problem and occurs across situations or partners.
The condition must cause marked distress or interpersonal difficulty and must not be explained by certain other factors specified in the product labelling.
How were the trials designed?
The RECONNECT programme included two similarly designed, randomised, double-blind, placebo-controlled phase 3 studies.
Researchers evaluated measures of sexual desire and distress.
What were the principal outcomes?
The trials reported statistically significant improvements in the prespecified measures of desire and associated distress compared with placebo.
Were the effects large?
The differences were generally modest.
Statistical significance should not be interpreted as a dramatic or universal response.
Did every participant benefit?
No.
Clinical responses varied, and the trials did not establish effectiveness for every participant.
What about satisfying sexual events?
The trials did not establish a statistically significant improvement over placebo in the number of satisfying sexual events, an important distinction from the primary desire and distress endpoints.
Why is this clinically important?
An improvement in a desire score does not necessarily correspond to a change in every aspect of sexual function.
Did the studies include all populations?
No.
The evidence supporting approval was specific to the population studied.
Scientific interpretation
PT-141 peptide research includes controlled human evidence supporting a particular prescription indication, but those findings should not be generalised to all forms of low desire or sexual dysfunction.
5. PT-141 Peptide Research and FDA Regulatory Status
Bremelanotide received initial FDA approval in 2019 as the active ingredient in Vyleesi.
The approval represents an important distinction between bremelanotide and many research-only peptides.
What is Vyleesi approved to treat?
Vyleesi is indicated for premenopausal women with acquired, generalised HSDD meeting the criteria in its prescribing information.
Is it approved for postmenopausal women?
No.
The product is not indicated for HSDD in postmenopausal women.
Is it approved for men?
No.
It is not indicated for HSDD in men.
Is it approved to enhance sexual performance?
No.
The official labelling explicitly excludes use for sexual performance enhancement.
Is it approved for every form of low desire?
No.
The indication excludes situations where low desire is attributable to certain coexisting medical or psychiatric conditions, relationship problems or medication effects.
Does approval apply to all PT-141 products?
No.
FDA approval applies to a specific regulated pharmaceutical product.
A laboratory vial labelled PT-141 is not automatically an approved or therapeutically interchangeable medicine.
What about research-only formulations?
Research materials may differ in their manufacturing, formulation, analytical specifications and quality controls.
They should not be represented as authorised prescription medicines.
Scientific interpretation
PT-141 peptide research must distinguish the established regulatory status of Vyleesi from the unverified status of independent research materials.
6. PT-141 Peptide Research: Adverse Effects and Cardiovascular Findings
Clinical development of bremelanotide generated important safety information.
The official product labelling describes adverse effects and specific contraindications.
Nausea
Nausea was a prominent adverse reaction in the clinical programme.
The prescribing information reports nausea in approximately 40% of participants receiving the approved product in the relevant clinical studies.
Other reported adverse reactions
Commonly reported effects included flushing, injection-site reactions, headache and vomiting.
Blood pressure changes
Bremelanotide can produce a transient increase in blood pressure.
The prescribing information also describes a corresponding reduction in heart rate.
Why is this relevant?
Cardiovascular responses can be clinically important, particularly in individuals with existing cardiovascular disease.
Contraindications
The approved product is contraindicated in people with uncontrolled hypertension or known cardiovascular disease.
Pigmentation changes
Focal hyperpigmentation has been reported, including changes involving the face, gums and breasts.
Some cases did not have confirmed resolution.
Why does pigmentation occur?
Activity at MC1R provides a plausible pharmacological explanation for pigmentation-related effects.
Oral medication interactions
The product labelling describes delayed gastric emptying and potential effects on the absorption of certain oral medicines.
An interaction involving oral naltrexone is specifically identified.
Does this establish the safety of research peptides?
No.
Clinical safety data from an approved formulation cannot be assumed to apply to an independently prepared laboratory material.
Scientific interpretation
PT-141 peptide research has generated clinically relevant adverse-effect information. Any account of the evidence that discusses potential benefits without these limitations would be incomplete.
7. PT-141 Peptide Research: Unresolved Questions and Evidence Limits
Despite established clinical development, several important questions remain.
Which receptor is responsible for the clinical effect?
MC4R is an important candidate, but bremelanotide has activity at multiple melanocortin receptors.
The precise mechanism underlying the approved clinical effect remains unknown.
Are the findings applicable to healthy individuals?
No.
The approved trials were not designed to establish enhancement of normal sexual function.
What about other psychiatric or neurological applications?
Experimental melanocortin biology does not establish bremelanotide as an approved treatment for unrelated psychiatric or neurological conditions.
What about male sexual dysfunction?
Earlier clinical development examined additional populations and indications.
Those investigations did not result in an FDA-approved bremelanotide product for men.
Are all melanocortin analogues equivalent?
No.
Different analogues may vary in receptor selectivity, potency, metabolism and adverse effects.
Can purity alone predict pharmacological activity?
No.
A chromatographic purity percentage cannot establish receptor potency, biological activity or clinical safety.
What further research is needed?
Research priorities include more precise receptor-pathway mapping, individual response variability and better understanding of the relationship between melanocortin signalling and clinical outcomes.
Scientific interpretation
PT-141 peptide research is supported by meaningful clinical evidence, but that evidence has specific boundaries and cannot justify unrestricted therapeutic claims.
PT-141 Peptide Research: Evidence Summary
| Research question | Evidence available | Interpretation |
|---|---|---|
| Chemical identity | Established | Synthetic cyclic heptapeptide |
| Melanocortin receptor activity | Strong preclinical evidence | Agonism at multiple receptor subtypes |
| MC4R-associated signalling | Molecular and animal studies | Important mechanistic hypothesis |
| Human HSDD outcomes | Two phase 3 controlled trials | Modest improvements in specified endpoints |
| Satisfying sexual events | Phase 3 trials | No significant difference versus placebo |
| FDA approval | Official regulatory documentation | Specific Vyleesi indication |
| Male sexual dysfunction | Historical development studies | No approved indication |
| Cardiovascular effects | Human clinical studies | Transient blood-pressure and heart-rate changes |
| Pigmentation | Clinical safety evidence | Recognised adverse effect |
| Research vial equivalence | Not established | Cannot infer pharmaceutical equivalence |
PT-141 Laboratory Testing: Identity, Purity and Stability
Reliable PT-141 peptide research requires analytical confirmation of the material being examined.
Molecular identity
Mass spectrometry can support identification by providing evidence consistent with the expected molecular mass.
Additional characterisation may be required to confirm the cyclic structure and distinguish related analogues.
HPLC purity
High-performance liquid chromatography can separate the intended peptide from certain impurities.
However, chromatographic main-peak area is not necessarily equivalent to absolute peptide content.
LC-MS analysis
Liquid chromatography–mass spectrometry can help identify the target compound and selected degradation products.
Stereochemistry
Bremelanotide contains a D-phenylalanine residue.
Stereochemistry matters because peptides with different stereochemical configurations may behave differently at receptors.
Cyclisation and structural integrity
The cyclised portion of the molecule contributes to its structure.
Related linear or incorrectly cyclised materials should not automatically be treated as equivalent.
Salt forms and counterions
Different supplied chemical forms can affect total material mass.
The nominal quantity in a vial should be distinguished from independently measured peptide content.
Stability
Stability depends on the exact formulation and environmental conditions.
Product-specific validated data are needed to support storage-life claims.
Batch documentation
A useful Certificate of Analysis identifies the compound, batch, analytical methods and results.
Sterility and endotoxins
HPLC and LC-MS do not establish sterility or endotoxin status.
These require separate testing where relevant.
Why this matters
PT-141 peptide research depends on reliable chemical identity, especially when comparing related melanocortin analogues with different receptor profiles.
Worked Example: Interpreting Melanocortin Receptor Data
Consider a hypothetical laboratory study measuring a cyclic AMP-associated response in cells expressing a melanocortin receptor.
| Experimental condition | Relative signal |
|---|---|
| Control | 1.00 |
| Experimental group A | 1.35 |
| Experimental group B | 2.10 |
| Experimental group C | 2.55 |
These values are fictional and illustrate data interpretation only.
What does the result suggest?
The experimental groups show higher measured signalling than the control.
Does this prove MC4R-specific activity?
No.
The study would require receptor-specific controls and appropriate comparative experiments.
Does a higher signal mean greater clinical effectiveness?
No.
A cell-based signalling response is not equivalent to a clinical outcome.
What additional information would help?
Relevant evidence includes receptor expression, assay validation, response variability and selectivity testing.
Main lesson
PT-141 peptide research must distinguish biochemical potency from the effectiveness and safety of a regulated pharmaceutical product.
PT-141 Compared With Other Melanocortin Peptides
| Compound | Structural or pharmacological distinction | Research context |
|---|---|---|
| Bremelanotide (PT-141) | Synthetic cyclic melanocortin agonist | Receptor pharmacology and approved HSDD medicine |
| Melanotan II | Related cyclic melanocortin analogue | Experimental pigmentation and behavioural effects |
| Alpha-MSH | Endogenous POMC-derived peptide | Melanocortin signalling |
| ACTH | Endogenous POMC-derived peptide | Adrenal steroidogenesis through MC2R |
| Semax | Synthetic ACTH-derived heptapeptide | Neurotrophin and gene-expression research |
Structural relationships do not establish equivalent clinical effects or safety.
Related Axion Peptide Lab research guides
Peptide Structure–Activity Relationships
Verify that these proposed internal links are live before publication.
PT-141 Research Materials and Axion Peptide Lab
Axion Peptide Lab provides a catalogue relevant to laboratory peptide research.
Researchers examining melanocortin signalling should review current catalogue information and available technical documentation.
What should laboratories verify?
Important specifications include chemical identity, cyclic structure, stereochemistry, chemical form, nominal content and batch documentation.
Does a research vial have the same status as Vyleesi?
No.
An independently supplied research material is not automatically equivalent to the FDA-approved prescription product.
Why is batch documentation important?
Batch-specific information helps connect laboratory results with the material actually tested.
What does research-only mean?
Research-only materials are intended for legitimate laboratory work and should not be represented as approved medicines or intended for human or veterinary administration.
Frequently Asked Questions About PT-141 Peptide Research
1. What is PT-141 peptide research?
PT-141 peptide research examines bremelanotide, a synthetic cyclic melanocortin receptor agonist, including its receptor pharmacology, clinical evidence and analytical characteristics.
2. Is PT-141 the same as bremelanotide?
Yes. PT-141 is a research designation for bremelanotide.
3. What receptors does PT-141 activate?
Bremelanotide interacts with several melanocortin receptor subtypes, including MC1R, MC3R and MC4R.
4. Is PT-141 an MC4R-selective agonist?
No. Its activity is not exclusive to MC4R.
5. Is bremelanotide FDA-approved?
Yes. Vyleesi is an FDA-approved bremelanotide prescription product for a specific indication in premenopausal women.
6. Is PT-141 approved for men?
No. Vyleesi is not indicated for men.
7. Does PT-141 enhance sexual performance?
Vyleesi is not indicated to enhance sexual performance. Its approval concerns a specifically defined desire disorder.
8. What adverse effects have been reported?
Clinical studies reported nausea, flushing, headache, injection-site reactions and other effects. Blood-pressure changes and focal hyperpigmentation are important warnings.
9. Is PT-141 the same as Melanotan II?
No. They are related but chemically distinct melanocortin analogues.
10. How can laboratories verify PT-141 quality?
Relevant approaches include HPLC, LC-MS, structural identity testing and batch-specific analytical documentation.
Conclusion: What PT-141 Peptide Research Establishes
PT-141 peptide research provides an unusually developed evidence base compared with many experimental peptide compounds.
Bremelanotide’s molecular identity and melanocortin receptor pharmacology are well characterised.
The RECONNECT phase 3 programme demonstrated modest improvements in selected clinical outcomes for a defined population of premenopausal women with acquired, generalised HSDD.
These results supported FDA approval of Vyleesi in 2019.
However, the approved indication is narrow, and the clinical mechanism remains incompletely understood.
Important adverse effects include nausea, transient cardiovascular changes and pigmentation-related reactions.
The existence of an approved pharmaceutical product does not establish the quality or clinical suitability of independently supplied PT-141 research materials.
For laboratories, accurate identification, suitable analytical methods and careful interpretation of receptor-specific findings remain essential.
PT-141 peptide research illustrates the difference between promising molecular pharmacology, demonstrated clinical outcomes and the strict regulatory boundaries of an approved medicine.
Scientific References
- DailyMed. Vyleesi (bremelanotide injection), current US prescribing information.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf - US Food and Drug Administration. Bremelanotide, multidisciplinary regulatory review, NDA 210557 (2019).
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf - Kingsberg SA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology.
https://pubmed.ncbi.nlm.nih.gov/?term=Kingsberg+Bremelanotide+Two+Randomized+Phase+3+Trials - Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide (2022).
https://pubmed.ncbi.nlm.nih.gov/35230162/ - ClinicalTrials.gov. Bremelanotide clinical research records.
https://clinicaltrials.gov/search?term=bremelanotide - IUPHAR/BPS Guide to Pharmacology. Melanocortin receptor pharmacology.
https://www.guidetopharmacology.org/ - PubMed. Bremelanotide melanocortin receptor research.
https://pubmed.ncbi.nlm.nih.gov/?term=bremelanotide+melanocortin+receptor - PubMed. Bremelanotide safety and cardiovascular research.
https://pubmed.ncbi.nlm.nih.gov/?term=bremelanotide+cardiovascular+safety
The cited pharmaceutical evidence applies to the products and conditions studied. It does not verify independently supplied research materials.
Research-use notice: This article is provided for scientific education and legitimate laboratory research. Axion Peptide Lab research materials are not intended for human or veterinary administration. The existence of FDA-approved bremelanotide does not establish the approval, safety or clinical suitability of independently supplied PT-141 materials. No administration instructions or individual medical recommendations are provided.